Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Depomed licenses Proquin XR to Esprit for $50 million
In return for exclusive marketing rights covering the US and Puerto Rico, Esprit will pay Depomed a $50 million license fee, consisting of $30 million payable upfront, $10
In return for exclusive marketing rights covering the US and Puerto Rico, Esprit will pay Depomed a $50 million license fee, consisting of $30 million payable upfront, $10
PTK 0796 is a novel, broad-spectrum antibiotic from the aminomethylcyclines (AMCs) antibiotic family, which has been shown to be highly effective in animal models at treating clinically prevalent
Introgen’s investment will be used to develop SR Pharma’s leading siRNA technology in the oncology area, including atuPLEX, its proprietary delivery system, which it has accessed through its
From its inception through to March 2005, Ibis has earned $38.5 million in revenue from government partners. An additional $13.6 million is committed under existing contracts and grants,
Encysive is seeking to market Thelin (sitaxsentan) as a 100 mg once daily oral treatment for patients with pulmonary arterial hypertension (PAH). The company filed an application to
The trial, part of a collaboration between AstraZeneca and Renovis, was originally expected to enroll 1,700 patients. The companies believe that based on enrollment trends to date, this
The planned interim analysis of an ongoing trial evaluating PTK/ZK suggests the drug does not increase overall survival when used as a second-line therapy in advanced colorectal cancer.
Ranbaxy plans to launch the alternative dosages in October this year, upon final regulatory approval. Glimepiride is indicated as an adjunct to diet and exercise to lower the
Schering AG possesses an advanced collection of identified SEGRAs, which could be used to treat a number of diseases. Schering and AstraZeneca will undertake a joint R&D program
The phase Ib study is a dose-escalation, multi-center trial evaluating the safety, immunogenicity, and efficacy of GI-5005. GI-5005 is designed to express antigens that fight hepatitis C infection